Barrington Research Issues Pessimistic Forecast for Dolby Laboratories (NYSE:DLB) Stock Price

Dolby Laboratories (NYSE:DLB) had its target price lowered by analysts at Barrington Research from $100.00 to $95.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the electronics maker’s stock. Barrington Research’s target price points to a potential upside of 45.87% from the company’s previous close.

Other analysts have also issued research reports about the company. Tigress Financial upped their target price on Dolby Laboratories from $112.00 to $114.00 and gave the stock a “buy” rating in a report on Friday, August 15th. Baird R W upgraded Dolby Laboratories to a “hold” rating in a research note on Friday, September 5th. Rosenblatt Securities set a $85.00 price objective on Dolby Laboratories and gave the company a “buy” rating in a research report on Wednesday. Wall Street Zen upgraded Dolby Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, August 30th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Dolby Laboratories in a report on Thursday, November 13th. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $92.00.

Dolby Laboratories Stock Performance

Dolby Laboratories stock opened at $65.13 on Wednesday. Dolby Laboratories has a fifty-two week low of $64.02 and a fifty-two week high of $89.66. The company has a market capitalization of $6.24 billion, a PE ratio of 23.86 and a beta of 0.97. The company has a 50 day moving average price of $68.93 and a 200-day moving average price of $72.51.

Dolby Laboratories (NYSE:DLB) last issued its earnings results on Tuesday, November 18th. The electronics maker reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.70 by $0.29. Dolby Laboratories had a net margin of 19.62% and a return on equity of 11.52%. The company had revenue of $307.02 million for the quarter, compared to analysts’ expectations of $305.76 million. During the same period in the prior year, the business earned $0.61 EPS. The firm’s quarterly revenue was up .7% on a year-over-year basis. Dolby Laboratories has set its FY 2026 guidance at 4.190-4.340 EPS. Q1 2026 guidance at 0.790-0.940 EPS. On average, analysts forecast that Dolby Laboratories will post 2.94 earnings per share for the current year.

Insider Transactions at Dolby Laboratories

In related news, CEO Kevin J. Yeaman sold 25,000 shares of the stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $68.87, for a total value of $1,721,750.00. Following the completion of the transaction, the chief executive officer directly owned 114,725 shares of the company’s stock, valued at $7,901,110.75. This trade represents a 17.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Shriram Revankar sold 7,000 shares of Dolby Laboratories stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $74.92, for a total transaction of $524,440.00. Following the completion of the sale, the senior vice president owned 70,435 shares of the company’s stock, valued at $5,276,990.20. This trade represents a 9.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 57,000 shares of company stock worth $4,037,690 in the last 90 days. Insiders own 38.39% of the company’s stock.

Institutional Investors Weigh In On Dolby Laboratories

Institutional investors and hedge funds have recently made changes to their positions in the stock. IFP Advisors Inc increased its position in shares of Dolby Laboratories by 12.4% in the 1st quarter. IFP Advisors Inc now owns 2,413 shares of the electronics maker’s stock valued at $194,000 after acquiring an additional 266 shares during the period. Allianz Asset Management GmbH grew its stake in Dolby Laboratories by 75.3% during the 1st quarter. Allianz Asset Management GmbH now owns 106,626 shares of the electronics maker’s stock valued at $8,563,000 after purchasing an additional 45,794 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Dolby Laboratories during the 1st quarter valued at about $1,011,000. Oak Thistle LLC acquired a new position in shares of Dolby Laboratories in the first quarter valued at about $1,356,000. Finally, Cetera Investment Advisers raised its stake in shares of Dolby Laboratories by 6.1% in the first quarter. Cetera Investment Advisers now owns 4,883 shares of the electronics maker’s stock worth $392,000 after purchasing an additional 282 shares during the last quarter. 58.56% of the stock is currently owned by institutional investors and hedge funds.

Dolby Laboratories Company Profile

Dolby Laboratories, Inc creates audio and imaging technologies that transform entertainment at the cinema, DTV transmissions and devices, mobile devices, OTT video and music services, home entertainment devices, and automobiles. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for a range of media applications; AVC, a digital video codec with high bandwidth efficiency used in various media devices; Dolby AC-4, a digital audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for cinema and various media devices.